INVESTOR PRESENTATION March 2017 A DIVERSIFIED CANNABIS TECHNOLOGY COMPANY

Size: px
Start display at page:

Download "INVESTOR PRESENTATION March 2017 A DIVERSIFIED CANNABIS TECHNOLOGY COMPANY"

Transcription

1 INVESTOR PRESENTATION March 2017 A DIVERSIFIED CANNABIS TECHNOLOGY COMPANY

2 Overview MJ BioPharma is a cannabis technology company led by a team of experienced business and medical professionals and researchers. Our expertise lies in extractions and custom formulations. We aim to develop and in-license best in class technologies and products for the medicinal and recreational markets in North America. 2

3 Investment Highlights A pharmaceutical based approach to developing cannabis products for medical and recreational markets Leadership team with international relationships in the fast growing medical and recreational cannabis industry Expertise developing innovative, effective, and precise cannabidiol (CBD), terpene and tetrahydrocannabinol (THC) based products Seeking to acquire or develop, best in class novel technologies and bring them to market Financial partners with experience in funding and creating value for shareholders in cannabis companies 3

4 Our Cannabis Business A revolution is taking place in North America and across the globe and the race to create a better, more sophisticated supply chain with medical grade, quality controlled, custom cannabis products is underway. MJ BioPharma is aiming to establish itself as a leader in this segment by acquiring and developing novel technologies with immediate term commercial applications. We are developing cannabidiol (CBD) delivery technologies such as a sublingual strip and a time release capsule, in addition to a range of oils for the medicinal and recreational markets. 4

5 About MJ BioPharma Vinergy Resources Ltd. (a publicly traded company on the CSE, trading under the symbol VIN) has an agreement to acquire MJ BioPharma with its cannabis assets, and majority interest in a Health Canada and Federal Drug Administration (FDA) licensed lab. Delivery Technologies Along with conventional systems, MJ BioPharma plans to offer the BURST delivery system built on natural botanical polymers delivering specially processed high purity cannabinoid complexes. The unique system for cannabinoid activation maintains the natural balance of THC, CBD, CBN and terpenes potentially delivering it to the body faster than any currently available delivery method. Development Lab Biolennia will provide a host of drug testing services and support to MJ BioPharma s product line. The facilities are already pursuing research and development into novel product formulation, safe extraction systems and complete quality management systems. 5

6 Our Technology Our process and approach set us apart from others in the industry: EXTRACTS We are experts at developing extracts and custom formulations. PRACTICES Our state-of-the-art lab services adhere to the latest standards for GMP, CGMP, ISO, EPA, FDA, CIFA, HACCP, OSHA, WHIMIS, and Health Canada. SCIENCE We use scientific methodology applied to a variety of formulations to achieve desired superior results. MANAGEMENT Our management is comprised of scientists, researchers, biochemists and business management personnel skilled in the development of cannabis and the business. 6

7 Market Key Facts Canada Canada, if legalized, is estimated at $5 billion in cannabis sales annually. US Markets The US market for marijuana in 2015 was $5.4 billion estimated is at $7.6 billion in total sales. Adding new markets legalizing, total could reach $20 billion within 3 years. Sources: *Sources: The Hemp Business Journal; Deloitte; 7

8 Milestones Since entering the cannabis sector MJ BioPharma has made major strides including moving the business in a new direction and establishing the company as a significant participant. DEC 2016 MJ BioPharma announces the signing of letter of intent to be acquired by Vinergy Resources Ltd. JAN 2017 Vinergy, a company for which MJ BioPharma has agreed to an LOI to be acquired, closes $2MM financing JAN 2017 Formed new Scientific Advisory Board (SAB) consisting of leading biopharma technology advisors FEB 2017 Announced BURST technology - a breakthrough in oral delivery of cannabinoids FEB 2017 Acquired 65% of Biolennia Labs, a Health Canada & FDA licensed lab 8

9 Immediate Strategy Through MJ BioPharma Develop our own unique extracts and custom formulations with unique processes and methodologies Develop numerous edible and oil products for the Medical and Recreational space Through Biolennia Labs Carry out R&D, develop and isolate formulations for use in medical and recreational applications. Currently in application process for a dealers license. Expansion Build a California and Nevada-licensed genetics breeding facility with extraction systems Add a dispensary license with our extraction and genetics partners 9

10 Founding Management The founding management of the company have a combined 30 years experience in the scientific, biopharma and cannabis industry. CEO MR.KENT A. DEUTERS Managed over 200 private label products for several Fortune 500 companies. 7 years of experience in the North American cannabis industry Commercialized delivery technologies and custom formulations for US based cannabis companies. DIRECTOR MR.JEREMY TOWNING Over 20 years of financial and real estate market experience Raised over $100MM in funding Extensive experience negotiating and executing on joint ventures SCIENTIFIC ADVISORY BOARD, CHAIR DR. WILL PANENKA M.D. and M.Sc. from the University of Calgary, Canada and Research Fellow, Harvard University. One of two specialists in Western Canada with unique dual specialties of neurology and psychiatry Extensive training and experience in drug use, addictions, and traumatic brain injury. SCIENTIFIC ADVISORY BOARD MR. JOHN SIMON Extensive experience in quality assurance and regulatory affairs under FDA and Health Canada audits of medical device and drug manufacturers, testing facilities, and clinical sites. Helped obtain, renew and maintain Drug Establishment Licenses (DEL), Medical Device Establishment Licenses (MDEL), and Licenses to Cultivate and Distribute under the Marihuana for Medical Purposes Regulations (MMPR) (now under the ACMPR) 10

11 Summary MJ BioPharma is positioned for diversification into both sides of the business; producing and refining cannabis products with support from experienced financial partners. P

12 Disclaimer IMPORTANT: PLEASE READ The information set forth in this document contains forward-looking statements. Statements in this document, which are not purely historical, are forward looking and include statements regarding beliefs, plans, expectations or intentions regarding the future. Except for the historical information presented herein, matters discussed in this document contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words as estimate, anticipate, believe, plan, intend, expect, may, should, or similar statements are forward-looking statements. Risks and uncertainties for the include, but are not limited to, the risks associated with the impact of general economic conditions in countries in which the conducts business, the impact of competitive products and pricing, product demand and market acceptance, new product development, the continuation and development of key customer and supplier relationships, and the availability of high-quality, qualified personnel and management. Other risks include, but are not limited to, factors affecting development and expansion activities generally including access to capital to meet all of the s financial requirements and the s ability to control costs. There can be no assurance that the s efforts will succeed and the will ultimately achieve sustained commercial success. These forwardlooking statements are made as of the date of this document, and the assumes no obligation to update the forward-looking statements, except as required by applicable securities laws, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the believes that the beliefs, plans, expectations and intentions contained in this document are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. This information contained in the document has been prepared by management of the, who takes full responsibility for its contents. This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the in any jurisdiction. 12

REVOLUTIONIZING HEALTH AND WELLNESS, IMPROVING LIVES WITH CANNABIS

REVOLUTIONIZING HEALTH AND WELLNESS, IMPROVING LIVES WITH CANNABIS REVOLUTIONIZING HEALTH AND WELLNESS, IMPROVING LIVES WITH CANNABIS State of the Nation Overall Summary 2016 A year of challenges 2017 Q1 - Return to strong growth, operations up and running Q2 - Close

More information

Disclaimers & Cautionary Statements

Disclaimers & Cautionary Statements Disclaimers & Cautionary Statements The information found herein, and any other materials provided by Cronos Group (the Company ), are intended solely for discussion purposes and are not intended as, and

More information

Technology and Compliance Platform for the Cannabis Industry

Technology and Compliance Platform for the Cannabis Industry Technology and Compliance Platform for the Cannabis Industry MassRoots, Inc. OTCQB: MSRT July 2017 Safe Harbor & Disclaimer This information does not constitute an offer to sell or a solicitation of an

More information

CSC Separating Into Two Industry Leading Public Companies. May 19, 2015

CSC Separating Into Two Industry Leading Public Companies. May 19, 2015 CSC Separating Into Two Industry Leading Public Companies May 19, 2015 Forward looking statements All written or oral statements made by CSC at this meeting or in these presentation materials that do not

More information

OTCQB: KSHB NICK KOVACEVICH OCTOBER 2017

OTCQB: KSHB NICK KOVACEVICH OCTOBER 2017 OTCQB: KSHB NICK KOVACEVICH OCTOBER 2017 Important Cautions Regarding Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions

More information

OTCQB: KSHB NICK KOVACEVICH JULY 2017

OTCQB: KSHB NICK KOVACEVICH JULY 2017 OTCQB: KSHB NICK KOVACEVICH JULY 2017 Important Cautions Regarding Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of

More information

For personal use only. Medical Nutrition Investment Company

For personal use only. Medical Nutrition Investment Company Medical Nutrition Investment Company Investment Focus Eve s vision is to be a leading Australia Investment company in the rapidly growing Global Medical Nutrition sector. Investing in businesses in the

More information

Investor Presentation

Investor Presentation Investor Presentation March 2018 TSX-V: ABCN 1 Disclaimer Certain information included in this presentation, which was prepared on January 8, 2018 speaks only as of such date, including any information

More information

Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)

Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

Presentation of 6M Figures BRAIN AG

Presentation of 6M Figures BRAIN AG Presentation of 6M Figures BRAIN AG BRAIN Key Enabler for a Biobased Economy Zwingenberg, May 31, 2016 BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.de +49 (0) 6251-9331-0 Disclaimer This

More information

HIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005

HIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or

More information

HPS vs. LED Indoor Cannabis Cultivation. Lasse Schulze (Ph.D.)

HPS vs. LED Indoor Cannabis Cultivation. Lasse Schulze (Ph.D.) HPS vs. LED Indoor Cannabis Cultivation Lasse Schulze (Ph.D.) Disclaimers & Cautionary Statements The information found herein, and any other materials provided by Cronos Group (the Company ), are intended

More information

MEDICAL MARIJUANA: TWEED: WHAT CAN HAPPEN IN A YEAR. TSXV:TWD

MEDICAL MARIJUANA: TWEED: WHAT CAN HAPPEN IN A YEAR. TSXV:TWD MEDICAL MARIJUANA: TWEED: WHAT CAN HAPPEN IN A YEAR. TSXV:TWD DISCLAIMER This presentation is not, and under no circumstances is to be construed as, a prospectus, offering memorandum, or advertisement

More information

Strengthening the experience and embracing the shift

Strengthening the experience and embracing the shift Strengthening the experience and embracing the shift THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL MARKETS EVENT AND IS PROVIDED

More information

SCIENTUS PHARMA. CORPORATE PRESENTATION October 2017

SCIENTUS PHARMA. CORPORATE PRESENTATION October 2017 SCIENTUS PHARMA CORPORATE PRESENTATION October 2017 FORWARD-LOOKING STATEMENTS This presentation contains certain forward looking statements and forward looking information (collectively referred to herein

More information

FOR SALE. State-of-the-Art cgmp-qualified Solid Dosage Development and Manufacturing Facility

FOR SALE. State-of-the-Art cgmp-qualified Solid Dosage Development and Manufacturing Facility FOR SALE State-of-the-Art cgmp-qualified Solid Dosage Development and Manufacturing Facility was purchased in 2015 by Ropack Pharma Solutions (RPS). RPS has made the strategic decision to market and sell

More information

AVINO SILVER & GOLD MINES LTD.

AVINO SILVER & GOLD MINES LTD. April 13, AVINO SILVER & GOLD MINES LTD. T 604.682.3701 Suite 900, 570 Granville Street ir@avino.com F 604.682.3600 Vancouver, BC V6C 3P1 www.avino.com NYSE-MKT: ASM TSX-V: ASM FSE: GV6 AVINO ANNOUNCES

More information

Disclaimer. 2

Disclaimer.  2 www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content

More information

THREE -YEAR STRATEGIC PLAN

THREE -YEAR STRATEGIC PLAN THREE -YEAR STRATEGIC PLAN 2017 18 2019 20 About ICES Population-based health research that makes a difference Since its inception in 1992, the Institute for Clinical Evaluative Sciences (ICES) has led

More information

Hydro takes over Vale s aluminium business in transforming transaction

Hydro takes over Vale s aluminium business in transforming transaction Hydro takes over Vale s aluminium business in transforming transaction Svein Richard Brandtzæg, President and CEO Bank of America Merrill Lynch Global Metals & Mining Conference May 12, 2010 (1) Cautionary

More information

Valmet unique offering with process technology, automation and services. Investor Lunch March 17, 2016 Kari Saarinen, CFO

Valmet unique offering with process technology, automation and services. Investor Lunch March 17, 2016 Kari Saarinen, CFO Valmet unique offering with process technology, automation and services Investor Lunch Kari Saarinen, CFO Agenda Investor lunch 1 2 Valmet s in brief Investment highlights 3 Area development 4 Conclusions

More information

Shareholder Update. April Dear Shareholders,

Shareholder Update. April Dear Shareholders, April 2017 Shareholder Update Brazil Po ta sh Corp, Sui t e 8 00, 6 5 Que e n St re et West, Toronto, O n M 5H 2 M5 www.potassio do bra s il.co m. br Dear Shareholders, During the first quarter of 2017,

More information

Biopharmaceuticals Investor & Analyst Day

Biopharmaceuticals Investor & Analyst Day Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative

More information

Responsible Investment in Sustainable Forestry

Responsible Investment in Sustainable Forestry Responsible Investment in Sustainable Forestry How do asset managers develop and execute RI strategies for timberland? Radha Kuppalli Director, Investor Services New Forests Pty Ltd rkuppalli@newforests.com.au

More information

Strategic Management. One Team. Infinite Solutions.

Strategic Management. One Team. Infinite Solutions. Strategic Management One Team. Infinite Solutions. Stantec's Strategic Management team combines business, financial, technical, and operational knowledge to develop solutions for our clients' capital

More information

KINGSMANN CARE GROUP

KINGSMANN CARE GROUP PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting

More information

Investor Presentation

Investor Presentation Siemens Ltd., 2 www.siemens.co.in Disclaimer This presentation has been prepared solely for use at the investor/analyst presentation. By attending the meeting where this presentation is made, or by reading

More information

IP Networks & Applications

IP Networks & Applications IP Networks & Applications Creating Value Through Applications & Analytics Bhaskar Gorti President, Applications & Analytics Our market is different from Nokia s Networks businesses 1. More fragmented

More information

Oppenheimer 16 th Annual Consumer Conference

Oppenheimer 16 th Annual Consumer Conference Oppenheimer 16 th Annual Consumer Conference Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements

More information

Investor Presentation September 2016

Investor Presentation September 2016 Investor Presentation September 2016 1 LEGAL DISCLAIMER Statements made by representatives for ATCO Ltd. and information provided in this presentation may be considered forward-looking statements. By their

More information

Inventergy Global, Inc. (NASDAQ: INVT), Target Price: $10.30)

Inventergy Global, Inc. (NASDAQ: INVT), Target Price: $10.30) Equity Telecom / Telecom Services Update (December 11, 2015) Inventergy Global, Inc. (NASDAQ: INVT), Target Price: $10.30) Based in Campbell, CA, Inventergy (NASDAQ: INVT, Inventergy ) is an intellectual

More information

Leader in Pharmaceutical Oral Films

Leader in Pharmaceutical Oral Films TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Oral Films WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation pharmaceutical products that address unmet medical

More information

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and

More information

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017 Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market

More information

INVESTOR PRESENTATION AUGUST 2017

INVESTOR PRESENTATION AUGUST 2017 INVESTOR PRESENTATION AUGUST 2017 Forward Looking Statements The information set forth in this document contains forward-looking statements. Statements in this document, which are not purely historical,

More information

uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value

uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington,

More information

2017 Annual Meeting of Shareholders

2017 Annual Meeting of Shareholders 2017 Annual Meeting of Shareholders May 17, 2017 The world leader in serving science Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following presentations about the company s

More information

16th Annual ICR XChange Conference January 14, 2014

16th Annual ICR XChange Conference January 14, 2014 16th Annual ICR XChange Conference January 14, 2014 Bill DeLaney President, Chief Executive Officer Chris Kreidler Executive Vice President, Chief Financial Officer Forward-Looking Statements Statements

More information

Global Manufacturing Industry Landscape

Global Manufacturing Industry Landscape Global Manufacturing Industry Landscape Tim Hanley, Deloitte Global Leader, Consumer & Industrial Products Industry group 2017 Manufacturing Forum. 17 October 2017. Perdue University What we will cover

More information

To unleash LeasePlan s potential in an exciting and dynamic market, we have defined a three-year strategic plan. Our strategic plan has three goals:

To unleash LeasePlan s potential in an exciting and dynamic market, we have defined a three-year strategic plan. Our strategic plan has three goals: 26 LeasePlan annual report 2016 What s next? 2017-2020 Our strategy To unleash LeasePlan s potential in an exciting and dynamic market, we have defined a three-year strategic plan. Our strategic plan has

More information

Birth of a world leader

Birth of a world leader PRESS RELEASE Birth of a world leader 26 April 2007 Net profit rose 13.6% to 458.2 million in the first quarter of 2007 IBERDROLA IS NOW ONE OF THE WORLD S LARGEST ELECTRICITY COMPANIES WITH THE SCOTTISHPOWER

More information

August Teligent, Inc. Jason Grenfell-Gardner CEO Jenniffer Collins CFO. NASDAQ Global Select: TLGT

August Teligent, Inc. Jason Grenfell-Gardner CEO Jenniffer Collins CFO. NASDAQ Global Select: TLGT August 2016, Inc. Jason Grenfell-Gardner CEO Jenniffer Collins CFO NASDAQ Global Select: TLGT Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements

More information

Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks

Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2017. With me

More information

Antisense Therapeutics Ltd ASX:ANP January 2017

Antisense Therapeutics Ltd ASX:ANP January 2017 Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential

More information

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives

More information

Delivering Energy Solutions

Delivering Energy Solutions Delivering Energy Solutions Meeting Energy Needs Homes and businesses across the country depend on energy to support the economy and sustain a high quality of life. Yet there s also a responsibility to

More information

Cell Therapy Services Your Product. Our Passion.

Cell Therapy Services Your Product. Our Passion. Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing

More information

Enactment of the Corporate Governance Policy

Enactment of the Corporate Governance Policy [Unofficial Translation] June 1, 2015 Koichiro Watanabe President and Representative Director The Dai-ichi Life Insurance Company, Limited Code: 8750 (TSE First section) Enactment of the Corporate Governance

More information

Enzyme Enabled Carbon Capture

Enzyme Enabled Carbon Capture Enzyme Enabled Carbon Capture Lowering the CCS Cost Barrier October 3, 2011 2011 CO2 Solutions Inc. and CO2 Solution Technologies Inc. All rights reserved Important Information About Forward Looking Statements

More information

OUR GUIDING PRINCIPLES

OUR GUIDING PRINCIPLES OUR GUIDING PRINCIPLES For some 50 years, the Green Bulletin series described the way John Deere conducted business and put its values into practice. The bulletins served as guides for the judgments and

More information

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

The Emerging Technology Program: FDA s Perspective

The Emerging Technology Program: FDA s Perspective The Emerging Technology Program: FDA s Perspective Mohan Sapru, M.S., Ph.D. Member Emerging Technology Team (ETT) CMC Lead Application Technical Lead Office of New Drug Products Office of Pharmaceutical

More information

APITOPE ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND LISTING ON EURONEXT BRUSSELS

APITOPE ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND LISTING ON EURONEXT BRUSSELS APITOPE ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND LISTING ON EURONEXT BRUSSELS HASSELT, Belgium, and CHEPSTOW, UK, 31 October 2017 - Apitope (the Company or Apitope ), a clinical

More information

BUCHANS MINERALS SUCCESSFULLY PRODUCES HIGH PURITY MANGANESE ELECTROLYTE FOR THE PRODUCTION OF ELECTROLYTIC MANGANESE METAL

BUCHANS MINERALS SUCCESSFULLY PRODUCES HIGH PURITY MANGANESE ELECTROLYTE FOR THE PRODUCTION OF ELECTROLYTIC MANGANESE METAL Head Office 247 Dill Road, RR 1 Windsor, NS, Canada, B0N 2T0 Trading Symbol: TSXV: BMC News Release No. 10-12 Shares Outstanding: 150,898,545 May 3 rd, 2012 T (902) 472 3520 F (902) 472 3521 www.buchansminerals.com

More information

Veterinarians Rely on Pacific Continental Bank

Veterinarians Rely on Pacific Continental Bank Veterinarians Rely on Pacific Continental Bank Just as veterinarians are committed to their patients welfare, Pacific Continental is committed to the financial health of veterinary clinics. We understand

More information

CB&I Investor Presentation March 2017

CB&I Investor Presentation March 2017 A World of Solutions CB&I Investor Presentation March 2017 A Leading Provider of Technology and Infrastructure for the Energy Industry Safe Harbor Statement This presentation contains forward-looking statements

More information

Portfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO

Portfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated

More information

company overview M A R C H

company overview M A R C H company overview MARCH 2016 our focus INNOVATION in Aesthetics and Dermatology DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION 2 / CONFIDENTIAL and PROPRIETARY the sienna opportunity CLEAR STRATEGY for

More information

Complex Generics: Charting a new path

Complex Generics: Charting a new path White paper Complex Generics: Charting a new path Complex generics offer a lucrative market for drug manufacturers, but only if they can adapt to a more complicated and challenging development process.

More information

Business Update: First Quarter 2007

Business Update: First Quarter 2007 Conference Call, April 19 th, 2007 Business Update: First Quarter 2007 Stefan Borgas, CEO Disclaimer Certain matters discussed in this presentation may constitute forwardlooking statements. These statements

More information

CITIZEN GREEN TECHNOLOGIES

CITIZEN GREEN TECHNOLOGIES Presents CITIZEN GREEN TECHNOLOGIES Forward Looking Statements This Presentation (together with any supplements and any other information that may be furnished to prospective investors by Global Cannabis

More information

INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!

INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.

More information

PRAXIS. A publication by Bioengineering AG

PRAXIS. A publication by Bioengineering AG PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.

More information

Financial and other information related to the intended combination of Intrum Justitia and Lindorff published by Intrum Justitia

Financial and other information related to the intended combination of Intrum Justitia and Lindorff published by Intrum Justitia Stockholm 12 June 08:10 CET (page 1 of 5) PRESS RELEASE Intrum Justitia AB (publ) Corporate identity no.:556607-7581 Financial and other information related to the intended combination of Intrum Justitia

More information

Helping unlock growth opportunities worldwide

Helping unlock growth opportunities worldwide Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product

More information

An Inbound Marketing & Sales SaaS Company

An Inbound Marketing & Sales SaaS Company 1 Safe Harbor This presentation includes certain forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning our cash flow and

More information

EU and FDA GMP Regulations: Overview and Comparison

EU and FDA GMP Regulations: Overview and Comparison THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational

More information

Recommended acquisition of The BSS Group plc. 5 July 2010

Recommended acquisition of The BSS Group plc. 5 July 2010 Recommended acquisition of The BSS Group plc 5 July 2010 Important information This document is being made available only to persons who fall within the exemptions contained in Article 19 and Article 49

More information

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where

More information

JAIBARAS DIAMOND PROJECT UPDATE

JAIBARAS DIAMOND PROJECT UPDATE JAIBARAS DIAMOND PROJECT UPDATE TSX-V STAR Market Release 11 July 2017 FIVE STAR DIAMONDS LIMITED Av. Jornalista Ricardo Marinho, 360 Ed. Cosmopolitan - Sala 113, CEP 22631-350 Barra da Tijuca - Rio de

More information

Enhancing Audit Committee Excellences through Internal Audit. 21 November 2017

Enhancing Audit Committee Excellences through Internal Audit. 21 November 2017 Enhancing Audit Committee Excellences through Internal Audit 21 November 2017 Sharpen and Strengthen Excellences of Audit Committee Recent Trends and Emerging Challenges Global and Emerging Trends Roles

More information

IF YOU WERE LIKE US, THEN YOU RE OVER USING ALL THESE PROGRAMS JUST TO GET TO KNOW YOUR CUSTOMER.

IF YOU WERE LIKE US, THEN YOU RE OVER USING ALL THESE PROGRAMS JUST TO GET TO KNOW YOUR CUSTOMER. PITCH PRESENTATION 2017 DISCLOSURE This document does not constitute an offer to sell or a solicitation of an offer to buy any securities. This document is an outline of matters for discussion only and

More information

121 MINING INVESTMENT CONFERENCE HONG KONG

121 MINING INVESTMENT CONFERENCE HONG KONG ASX / MEDIA RELEASE 23 April 2018 121 MINING INVESTMENT CONFERENCE HONG KONG St George Mining Limited (ASX: SGQ) ( St George or the Company ) is participating at the 121 Mining Investment Conference in

More information

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009 Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the

More information

Quintiles Transnational Corporation Big is Beautiful

Quintiles Transnational Corporation Big is Beautiful Company Overview Quintiles Transnational Corporation Big is Beautiful Quintiles Transnational is the market leader in providing a full range of integrated product development and commercial development

More information

The Northwest Seaport Alliance Transition Plan DRAFT AS OF 5/5/15

The Northwest Seaport Alliance Transition Plan DRAFT AS OF 5/5/15 The Northwest Seaport Alliance Transition Plan DRAFT AS OF 5/5/15 1.0 Introduction This document fulfills requirements for a Transition Plan as defined in the Framework ILA. It defines the steps and timeframes

More information

Key Definitions 6/16/2015

Key Definitions 6/16/2015 Technology Transfer from a CDMO Perspective Joe Cobb, CPIP Director, Pharmaceutical Development Metrics Contract Services, a division of Mayne Pharma US 18-June-2015 Key Definitions CDMO Contract Development/Manufacturing

More information

Bemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference

Bemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference Bemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference September 14, 2011 Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the

More information

Illegal Drugs & Pharma: Kingpins of New Risk

Illegal Drugs & Pharma: Kingpins of New Risk Illegal Drugs & Pharma: Kingpins of New Risk Dan Frechtling, Chief Product Officer, G2 Web Services Dione Hodges, Senior Risk Management Director, Sterling Payment Technologies 03/31/2016 MAC is an organization

More information

Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris

Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris This press release cannot be published, transmitted or distributed, directly or indirectly, in the United States, South Africa, Canada, Australia or Japan. This press release does not constitute an offer

More information

Process and Architecture Overview IDMP Identification of Medicinal Products. Sven Eller, Life Sciences Solution Engagement Manager

Process and Architecture Overview IDMP Identification of Medicinal Products. Sven Eller, Life Sciences Solution Engagement Manager Process and Architecture Overview IDMP Identification of Medicinal Products Sven Eller, Life Sciences Solution Engagement Manager Legal Disclaimer The information in this document is confidential and proprietary

More information

LA-Z-BOY INCORPORATED

LA-Z-BOY INCORPORATED LA-Z-BOY INCORPORATED November 2017 Providing comfort to America for 90 years FORWARD-LOOKING DISCLAIMER This presentation contains forward-looking statements that involve uncertainties and risks as detailed

More information

CBRE INDUSTRIAL & LOGISTICS ADVISORY & TRANSACTION SERVICES

CBRE INDUSTRIAL & LOGISTICS ADVISORY & TRANSACTION SERVICES CBRE INDUSTRIAL & LOGISTICS ADVISORY & TRANSACTION SERVICES CBRE Industrial & Logistics Services represents the largest industrial services platform in the world, offering an integrated suite of advisory,

More information

Group Management and Productivity Enhancement by Shinsei Bank Group

Group Management and Productivity Enhancement by Shinsei Bank Group Management and Productivity Enhancement by Shinsei Bank February, 2018 Akira Hirasawa Chief Officer of Organizational Strategy Headquarters Shinsei Bank, Limited Direction of Management Establish unique

More information

Idorsia Company Profile

Idorsia Company Profile Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has

More information

Comparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017

Comparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017 Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical

More information

News Release. Even more attractive to life science and fine chemical industries. Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21

News Release. Even more attractive to life science and fine chemical industries. Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21 Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21 Even more attractive to life science and fine chemical industries Saltigo GmbH Contact: Ilona Kawan LANXESS AG Corporate Communications

More information

Investor Presentation February 2018 Slide 1. Investor Presentation February 2018

Investor Presentation February 2018 Slide 1. Investor Presentation February 2018 Investor Presentation February 2018 Slide 1 Investor Presentation February 2018 Forward Looking Statements Statements made during this presentation that set forth expectations, predictions, projections

More information

Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical

Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical February 26, 2008 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings

More information

How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab

How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx

More information

A full-service CRO with integrated early-stage capabilities

A full-service CRO with integrated early-stage capabilities CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March

More information

Executive Recruitment

Executive Recruitment Executive Recruitment Design Build Attract No margin for error. The most powerful business decision you will ever make is selecting the executives you hire. There are thousands of executive candidates

More information

Quality Agreements and Managing Contract Supplier Quality

Quality Agreements and Managing Contract Supplier Quality Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract

More information

POSITION DESCRIPTION June 16, 2017

POSITION DESCRIPTION June 16, 2017 POSITION DESCRIPTION June 16, 2017 Common Name: Classification: Team / Section: Bureau / Division: ROOFING / BUILDING ENVELOPE PROJECT MANAGER ENGINEERING SPECIALIST MANAGEMENT Project Delivery Services

More information

Breaking the Silo Mentality Working With Opinion Leaders

Breaking the Silo Mentality Working With Opinion Leaders CBI s 2 nd Annual KOL Conference Breaking the Silo Mentality Working With Opinion Leaders Kashif Chaudhry Objectives Share a view on the changing environment impacting the pharmaceutical industry and KOL

More information

New Cardinal Health (Post-Spin)

New Cardinal Health (Post-Spin) New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009

More information

Guidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.

Guidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd. Guidance for Industry Process Validation: General Principles and Practices D M k T k Dr. Mark Tucker, F. Hoffman-La Roche, Ltd. Disclosures I am currently a Senior Technical Advisor at F. Hoffman -La Roche.

More information

AT&T INC. CORPORATE GOVERNANCE GUIDELINES

AT&T INC. CORPORATE GOVERNANCE GUIDELINES AT&T INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors of AT&T Inc. ("AT&T") acting on the recommendation of its Corporate Governance and Nominating Committee, has developed and adopted the following

More information